Exploring the dark proteome and why it represents a critical, underexplored frontier in understanding and treating disease.
Exploring the dark proteome and why it represents a critical, underexplored frontier in understanding and treating disease.
See how our methods enable deep coverage in diverse biofluids & tissue, and are scalable to your throughput needs.
Our comprehensive Metabolite Standards Library enhances the speed, quality, and extent of metabolite identification.
How multi-omics profiling of disease accelerates new target discovery, clinical trials, and alignment of patients & therapies.
This paper describes a new approach to metabolite ID & how it was used to discover a novel metabolite biomarker.
How multimodal longitudinal datasets can be leveraged to improve therapeutic development and patient outcomes.
Explore advancements finally allowing drug developers to extract maximal biological insight from the plasma proteome.
Discussing how multiple innovation cycles are aligning in the “year of proteomics” to drive better, faster drug development.
See how these assays offer an in-depth approach to non-invasively probe systemic health and enable decentralized clinical trials.
How is the ability to more broadly probe human biology enabling more precise & targeted drug development?
